CollPlant Biotechnologies (CLGN) Accumulated Expenses (2019 - 2025)

CollPlant Biotechnologies' Accumulated Expenses history spans 7 years, with the latest figure at $605000.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 499.01% year-over-year to $605000.0; the TTM value through Dec 2025 reached $605000.0, up 499.01%, while the annual FY2025 figure was $605000.0, 499.01% up from the prior year.
  • Accumulated Expenses reached $605000.0 in Q4 2025 per CLGN's latest filing, up from $101000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.4 million in Q4 2021 to a low of $101000.0 in Q4 2024.
  • Average Accumulated Expenses over 5 years is $726600.0, with a median of $605000.0 recorded in 2025.
  • Peak YoY movement for Accumulated Expenses: tumbled 90.4% in 2024, then surged 499.01% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $1.4 million in 2021, then tumbled by 68.79% to $446000.0 in 2022, then skyrocketed by 135.87% to $1.1 million in 2023, then crashed by 90.4% to $101000.0 in 2024, then soared by 499.01% to $605000.0 in 2025.
  • Per Business Quant, the three most recent readings for CLGN's Accumulated Expenses are $605000.0 (Q4 2025), $101000.0 (Q4 2024), and $1.1 million (Q4 2023).